3-iodobenzylguanidine has been researched along with Cardiac Conduction Defect in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amanullah, A; Gupta, S | 1 |
| Ebihara, Y; Ishii, N; Mochizuki, H; Nagamachi, S; Nakazato, M; Shiomi, K; Taniguchi, A; Ugawa, Y | 1 |
1 review(s) available for 3-iodobenzylguanidine and Cardiac Conduction Defect
| Article | Year |
|---|---|
Radionuclide imaging of cardiac sympathetic innervation in heart failure: unlocking untapped potential.
Topics: 3-Iodobenzylguanidine; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Cardiac Resynchronization Therapy; Cardiomyopathies; Cardiotoxicity; Death, Sudden, Cardiac; Ephedrine; Heart; Heart Conduction System; Heart Failure; Heart Transplantation; Humans; Prognosis; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon | 2015 |
1 other study(ies) available for 3-iodobenzylguanidine and Cardiac Conduction Defect
| Article | Year |
|---|---|
PR Prolongation and Cardiac 123I-MIBG Uptake Reduction in Parkinson's Disease.
Topics: 3-Iodobenzylguanidine; Aged; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Electrocardiography; Female; Heart Conduction System; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinson Disease; Radiopharmaceuticals | 2015 |